Biotech News News 11 August 2025

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Stock Performance and Recent Rally Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day Marketbeat. (On Oct 21, REPL was trading

21 October 2025

Biotech News·FDA Approvals·Financial Markets·Investment Analysis·Stock Market

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche Reuters)

18 October 2025

Biotech News·Investment Analysis·Pharmaceuticals·Stock Market

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Key Facts – October 18, 2025 RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price erupted on Friday, Oct. 17, 2025, after the company unveiled its game-changing pharma partnership and a significant financing boost. In pre-market trading, RANI

18 October 2025

Biotech News·Investing·Mergers & Acquisitions·Pharmaceutical Industry·Stock Market

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to

17 October 2025

Biotech News·FDA Approvals·Financial Analysis·Investment Strategies·Stock Market

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed that Thursday at $162.71, up over 183% in

17 October 2025

Biotech News·Clinical Trials·Financial Trends·Investment Analysis·Stock Market

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market.

16 October 2025

Biotech News·FDA Approvals·Investment Insights·Pharmaceuticals·Stock Market

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-October Stockinvest, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data

16 October 2025

AI Technology·Biotech News·Financial Analysis·Investing·Stock Market

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in

16 October 2025

Biotech News·Cancer Research·Investment Insights·Stock Market

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech Fiercebiotech; MarketBeat and DirectorsTalk analyst surveys Marketbeat Directorstalkinterviews; Economic Times deal summary Indiatimes Indiatimes; Business Wire legal alert Businesswire Businesswire; and TradingView market data Marketbeat Tradingview.

9 October 2025

Biotech News·Investment Insights·Mergers & Acquisitions·Pharma Industry·Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling

6 October 2025

Biotech News·Investment Analysis·Pharma Industry·Stock Market

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in

25 September 2025

Biotech News·Company Analysis·Financial Trends·Investing·Stock Market

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade.

11 August 2025

Biotech News·FDA Approvals

Biotech News News 11 August 2025 - 21 October 2025